SG11201704758XA - Synthetic apelin fatty acid conjugates with improved half-life - Google Patents

Synthetic apelin fatty acid conjugates with improved half-life

Info

Publication number: SG11201704758XA
Authority: SG; Singapore
Prior art keywords: life; fatty acid; acid conjugates; improved half; synthetic apelin
Prior art date: 2015-01-23

Aimee Richardson Usera

Frederic Zecri

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-15Application filed by Novartis AgfiledCriticalNovartis Ag

2017-08-30Publication of SG11201704758XApublicationCriticalpatent/SG11201704758XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Diabetes (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)

SG11201704758XA2015-01-232016-01-15Synthetic apelin fatty acid conjugates with improved half-lifeSG11201704758XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562107040P	2015-01-23	2015-01-23
PCT/IB2016/050206WO2016116842A1 (en)	2015-01-23	2016-01-15	Synthetic apelin fatty acid conjugates with improved half-life

Publications (1)

Publication Number	Publication Date
SG11201704758XAtrue SG11201704758XA (en)	2017-08-30

Family

ID=55229773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201704758XASG11201704758XA (en)	2015-01-23	2016-01-15	Synthetic apelin fatty acid conjugates with improved half-life

Country Status (22)

Country	Link
US (1)	US9931372B2 (en)
EP (1)	EP3247405B1 (en)
JP (1)	JP2018507187A (en)
KR (1)	KR20170103970A (en)
CN (1)	CN107406490A (en)
AR (1)	AR104479A1 (en)
AU (1)	AU2016209968B2 (en)
BR (1)	BR112017014194A2 (en)
CA (1)	CA2972871A1 (en)
CO (1)	CO2017007244A2 (en)
CR (1)	CR20170338A (en)
CU (1)	CU20170093A7 (en)
EA (1)	EA201791668A1 (en)
IL (1)	IL253105A0 (en)
MA (1)	MA41580A (en)
MX (1)	MX2017009534A (en)
PE (1)	PE20171328A1 (en)
PH (1)	PH12017501112A1 (en)
SG (1)	SG11201704758XA (en)
TW (1)	TW201632197A (en)
UY (1)	UY36523A (en)
WO (1)	WO2016116842A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
KR102396217B1 (en)*	2017-09-19	2022-05-09	임문워크 아이엔씨	Pharmaceutical constructs with increased binding affinity to albumin
WO2019229242A1 (en)	2018-05-31	2019-12-05	Novo Nordisk A/S	Derivatives comprising an apelin analogue and uses thereof
TW202304500A (en)*	2021-04-21	2023-02-01	瑞士商諾華公司	Glucagon like peptide compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2951135A1 (en)	1979-12-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
US4617307A (en)	1984-06-20	1986-10-14	Ciba-Geigy Corporation	Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en)	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
DE3347565A1 (en)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	NEW PHENYL ACETIC DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
JPS6354321A (en)	1985-03-27	1988-03-08	Ajinomoto Co Inc	Blood sugar lowering agent
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
JP3262329B2 (en)	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	GLP-1 analog useful for the treatment of diabetes
AU654331B2 (en)	1991-03-30	1994-11-03	Kissei Pharmaceutical Co. Ltd.	Succinic acid compounds
US5155100A (en)	1991-05-01	1992-10-13	Ciba-Geigy Corporation	Phosphono/biaryl substituted dipeptide derivatives
RU2086544C1 (en)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
DE10075006I2 (en)	1991-06-21	2004-01-08	Boehringer Ingelheim Pharma	Use of (S) (+) - 2-ethoxy-4- [N- [1- (2-piperidino-phenyl) -3-methyl-1-butyl [aminocarbonylmethyl] benzoic acid for the manufacture of a long-term antidiabetic.
DE69217762T2 (en)	1991-07-30	1997-10-09	Ajinomoto Kk	Crystals of N- (Trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine and process for their preparation
EP0618803A4 (en)	1991-12-19	1995-03-22	Southwest Found Biomed Res	Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments.
DK0712389T3 (en)*	1993-08-02	2001-06-05	Commw Scient Ind Res Org	Therapeutic compound - fatty acid conjugates
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (en)	1994-12-20	1997-08-21	Hoffmann La Roche
DE122010000020I1 (en)	1996-04-25	2010-07-08	Prosidion Ltd	Method for lowering the blood glucose level in mammals
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
ATE383424T1 (en)	1997-12-24	2008-01-15	Takeda Pharmaceutical	POLYPEPTIDES, THEIR PRODUCTION AND USE
WO1999043357A1 (en)*	1998-02-25	1999-09-02	Micrologix Biotech Inc.	Indolicidin and cationic peptides conjugated with polymers
GT199900147A (en)	1998-09-17	1999-09-06		1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (en)	1998-12-10	2002-04-29	Novartis Ag	COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6723752B2 (en)	1999-09-23	2004-04-20	Pharmacia Corporation	(R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US7635751B2 (en)	2000-03-23	2009-12-22	Takada Pharmaceutical Company Limited	Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof
KR20020089437A (en)	2000-04-12	2002-11-29	노파르티스 아게	Combination of organic compounds
JP2004537984A (en)	2001-04-19	2004-12-24	ザスクリップスリサーチインスティテュート	Methods and compositions for producing orthogonal tRNA-aminoacyl tRNA synthetase pairs
CA2466034C (en)	2001-11-08	2012-12-18	Protein Design Labs, Inc.	Stable aqueous pharmaceutical formulations of daclizumab antibodies
AU2003232941A1 (en)	2002-06-07	2003-12-22	Glaxo Group Limited	N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
JP4533139B2 (en)	2002-08-07	2010-09-01	ノバルティスアーゲー	Organic compounds as treatments for aldosterone-mediated conditions
CA2505752A1 (en)	2002-11-18	2004-06-03	Novartis Ag	Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
EP1626981A4 (en)*	2003-03-04	2006-11-22	Biorexis Pharmaceutical Corp	Dipeptidyl-peptidase protected proteins
ATE433984T1 (en)	2004-03-26	2009-07-15	Lilly Co Eli	COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
UA90269C2 (en)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Tetrahydroquinoline derivatives and a process for preparing the same
JP5179174B2 (en)	2004-05-28	2013-04-10	ノバルティスファーマアーゲー	Tetrahydro-imidazo [1,5-A] pyridine derivatives as aldosterone synthase inhibitors
US20080076794A1 (en)	2004-05-28	2008-03-27	Peter Herold	Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
TW200611898A (en)	2004-05-28	2006-04-16	Speedel Experimenta Ag	Organic compounds
AR049711A1 (en)	2004-07-09	2006-08-30	Speedel Experimenta Ag	HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE
TW200716105A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Imidazole compounds
TW200716636A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
TW200716634A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
GT200600381A (en)	2005-08-25	2007-03-28		ORGANIC COMPOUNDS
US8673848B2 (en)*	2012-01-27	2014-03-18	Novartis Ag	Synthetic apelin mimetics for the treatment of heart failure
TW200804378A (en)	2005-12-09	2008-01-16	Speedel Experimenta Ag	Organic compounds
TW200738261A (en)	2005-12-20	2007-10-16	Bristol Myers Squibb Co	Stable protein formulations
US20090156875A1 (en)	2006-04-04	2009-06-18	Takafumi Tomioka	Methane separation method, methane separation apparatus, and methane utilization system
TW200808812A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
TW200808813A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
MX2008014284A (en)	2006-05-10	2008-11-18	Novartis Ag	Bicyclic derivatives as cetp inhibitors.
EP1886695A1 (en)	2006-06-27	2008-02-13	Speedel Experimenta AG	Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
WO2008009435A1 (en)	2006-07-20	2008-01-24	Novartis Ag	Amino-piperidine derivatives as cetp inhibitors
KR20090055595A (en)	2006-08-25	2009-06-02	노파르티스 아게	Fusion imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and / or 11-beta-hydroxylase and / or aromatase
US7834164B2 (en)*	2006-10-25	2010-11-16	Amgen Inc.	DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression
JP2010513558A (en)	2006-12-18	2010-04-30	ノバルティスアーゲー	4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone / 11-beta-hydroxylase inhibitors
BRPI0721290A2 (en)	2006-12-18	2014-03-25	Novartis Ag	ORGANIC COMPOUNDS
EA200900811A1 (en)	2006-12-18	2009-12-30	Новартис Аг	IMIDAZOLES AS ANALYSTERONSYNTASE INHIBITORS
ES2354008T3 (en)	2007-03-29	2011-03-09	Novartis Ag	SPIROHETEROCYCLIC COMPOUNDS.
TWI448284B (en)	2007-04-24	2014-08-11	Theravance Inc	Dual-acting antihypertensive agents
JP2010538071A (en)	2007-09-07	2010-12-09	セラヴァンス，インコーポレーテッド	Dual acting antihypertensive
AU2008324243B2 (en)	2007-11-05	2012-03-08	Novartis Ag	4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
AU2008333272B2 (en)	2007-12-03	2012-03-29	Novartis Ag	1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
JP2011518884A (en)	2008-04-29	2011-06-30	セラヴァンス，インコーポレーテッド	Dual active antihypertensive
AR072297A1 (en)	2008-06-27	2010-08-18	Novartis Ag	DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
MX2011000847A (en)*	2008-08-06	2011-02-25	Novo Nordisk Healthcare Ag	Conjugated proteins with prolonged in vivo efficacy.
KR101316159B1 (en)	2008-10-24	2013-10-15	아이알엠 엘엘씨	Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
US20120028888A1 (en)*	2008-11-04	2012-02-02	Jay Janz	Apj receptor compounds
RS53275B (en)	2009-05-15	2014-08-29	Novartis Ag	Aryl pyridine as aldosterone synthase inhibitors
MA33364B1 (en)	2009-05-28	2012-06-01	Novartis Ag	SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS
EP2594557B1 (en)	2009-05-28	2016-08-10	Novartis AG	Substituted aminopropionic derivatives as neprilysin inhibitors
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
PL2525834T3 (en)*	2010-01-22	2020-10-19	Novo Nordisk Health Care Ag	Growth hormones with prolonged in-vivo efficacy
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
BR112012028707A2 (en)	2010-05-13	2019-09-24	Univ Indiana Res & Tech Corp	glucagon compound of the peptide superfamily exhibiting g receptor activity with coupled protein, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
PL2683360T3 (en)	2011-03-11	2016-09-30		Pegylated apelin and uses thereof
US20150011466A1 (en)*	2012-01-09	2015-01-08	Anchor Therapeutics, Inc.	APJ Receptor Compounds
US20160067347A1 (en)	2012-12-20	2016-03-10	Amgen Inc.	Apj receptor agonists and uses thereof
ES2708957T3 (en)	2013-03-14	2019-04-12	Regeneron Pharma	Appeline fusion proteins and uses thereof
CN105705167A (en)*	2013-07-25	2016-06-22	诺华股份有限公司	Bioconjugates of synthetic APELIN polypeptides
EP3024845A1 (en)*	2013-07-25	2016-06-01	Novartis AG	Cyclic polypeptides for the treatment of heart failure
AU2015274574B2 (en)	2014-06-10	2019-10-10	Amgen Inc.	Apelin polypeptides
US10588980B2 (en)*	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
EP3237435B1 (en)	2014-12-23	2023-05-24	INSERM - Institut National de la Santé et de la Recherche Médicale	Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor

2016
- 2016-01-15USUS14/996,418patent/US9931372B2/enactiveActive
- 2016-01-15BRBR112017014194Apatent/BR112017014194A2/ennot_activeIP Right Cessation
- 2016-01-15EPEP16701560.1Apatent/EP3247405B1/enactiveActive
- 2016-01-15CACA2972871Apatent/CA2972871A1/ennot_activeAbandoned
- 2016-01-15KRKR1020177022999Apatent/KR20170103970A/ennot_activeWithdrawn
- 2016-01-15WOPCT/IB2016/050206patent/WO2016116842A1/enactiveApplication Filing
- 2016-01-15MAMA041580Apatent/MA41580A/enunknown
- 2016-01-15SGSG11201704758XApatent/SG11201704758XA/enunknown
- 2016-01-15AUAU2016209968Apatent/AU2016209968B2/ennot_activeCeased
- 2016-01-15JPJP2017538728Apatent/JP2018507187A/enactivePending
- 2016-01-15CUCUP2017000093Apatent/CU20170093A7/enunknown
- 2016-01-15PEPE2017001257Apatent/PE20171328A1/ennot_activeApplication Discontinuation
- 2016-01-15CNCN201680006640.0Apatent/CN107406490A/enactivePending
- 2016-01-15MXMX2017009534Apatent/MX2017009534A/enunknown
- 2016-01-15CRCR20170338Apatent/CR20170338A/enunknown
- 2016-01-15EAEA201791668Apatent/EA201791668A1/enunknown
- 2016-01-20UYUY0001036523Apatent/UY36523A/ennot_activeApplication Discontinuation
- 2016-01-22TWTW105102112Apatent/TW201632197A/enunknown
- 2016-01-22ARARP160100180Apatent/AR104479A1/enunknown
2017
- 2017-06-15PHPH12017501112Apatent/PH12017501112A1/enunknown
- 2017-06-22ILIL253105Apatent/IL253105A0/enunknown
- 2017-07-19COCONC2017/0007244Apatent/CO2017007244A2/enunknown

Also Published As

Publication number	Publication date
TW201632197A (en)	2016-09-16
MA41580A (en)	2017-11-29
EA201791668A1 (en)	2017-11-30
CR20170338A (en)	2017-09-12
AR104479A1 (en)	2017-07-26
BR112017014194A2 (en)	2018-01-09
UY36523A (en)	2016-08-31
KR20170103970A (en)	2017-09-13
EP3247405A1 (en)	2017-11-29
CN107406490A (en)	2017-11-28
PE20171328A1 (en)	2017-09-12
AU2016209968B2 (en)	2018-11-29
US9931372B2 (en)	2018-04-03
PH12017501112A1 (en)	2017-11-27
US20160213743A1 (en)	2016-07-28
IL253105A0 (en)	2017-08-31
MX2017009534A (en)	2018-04-10
AU2016209968A1 (en)	2017-07-20
CU20170093A7 (en)	2017-09-06
CA2972871A1 (en)	2016-07-28
WO2016116842A1 (en)	2016-07-28
JP2018507187A (en)	2018-03-15
CO2017007244A2 (en)	2017-10-10
EP3247405B1 (en)	2019-07-17
WO2016116842A9 (en)	2016-12-08

Publication	Publication Date	Title
IL285516B (en)	2022-04-01	Amatoxin-antibody conjugates
ZA201704297B (en)	2022-05-25	Pyrrolobenzodiazepine-antibody conjugates
PT3119885T (en)	2021-08-02	Antibody-fynomer conjugates
SG11201610596PA (en)	2017-01-27	Lipid comprising docosapentaenoic acid
GB201319274D0 (en)	2013-12-18	The press-on footwear
GB201513607D0 (en)	2015-09-16	Pyrrolobenzodiazepine-antibody conjugates
SG11201605988XA (en)	2016-09-29	Carton with retention features
IL253105A0 (en)	2017-08-31	Synthetic apelin fatty acid conjugates with improved half-life
ZA201506914B (en)	2017-01-25	Phosphorus-sparing nutritional composition
SG11201505452TA (en)	2015-08-28	Anti-regurgitation nutritional composition
SG11201706875QA (en)	2017-09-28	Towing assembly
IL256199A (en)	2018-02-28	Multi-peptide composition
IL249842A0 (en)	2017-02-28	Lipid comprising docosapentaenoic acid
PL3270711T3 (en)	2019-05-31	Sugar-dipeptide conjugates
SG10201506686WA (en)	2017-03-30	Conjugates
GB2528274B (en)	2017-11-08	Responsive design with push messages
GB201310946D0 (en)	2013-07-31	Antidote
IL252360A0 (en)	2017-07-31	Sugar-dipeptide conjugates as flavor molecu
GB201518839D0 (en)	2015-12-09	Conjugates
GB201513605D0 (en)	2015-09-16	Pyrrolobenzodiazepine-antibody conjugates
GB201521142D0 (en)	2016-01-13	Chalk
GB201515215D0 (en)	2015-10-14	Concept CC
GB201509535D0 (en)	2015-07-15	Chalk
GB201420910D0 (en)	2015-01-07	Pyrrolobenzodiazepine-antibody conjugates
GB201406720D0 (en)	2014-05-28	Pyrrolobenzodiazepine-antibody conjugates

Movatterモバイル変換

SG11201704758XA - Synthetic apelin fatty acid conjugates with improved half-life - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=55229773

Family Applications (1)

Country Status (22)

Families Citing this family (4)

Family Cites Families (86)

Also Published As

Similar Documents